ALT
Price
$8.25
Change
+$0.07 (+0.86%)
Updated
Dec 20 closing price
96 days until earnings call
EDIT
Price
$1.32
Change
-$0.02 (-1.49%)
Updated
Dec 20, 04:59 PM (EDT)
67 days until earnings call
Ad is loading...

ALT vs EDIT

Header iconALT vs EDIT Comparison
Open Charts ALT vs EDITBanner chart's image
Altimmune
Price$8.25
Change+$0.07 (+0.86%)
Volume$4.9M
CapitalizationN/A
Editas Medicine
Price$1.32
Change-$0.02 (-1.49%)
Volume$102.27K
CapitalizationN/A
ALT vs EDIT Comparison Chart
Loading...
ALT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EDIT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ALT vs. EDIT commentary
Dec 21, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALT is a Hold and EDIT is a Hold.

COMPARISON
Comparison
Dec 21, 2024
Stock price -- (ALT: $8.27 vs. EDIT: $1.31)
Brand notoriety: ALT and EDIT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ALT: 140% vs. EDIT: 159%
Market capitalization -- ALT: $587.85M vs. EDIT: $108.14M
ALT [@Biotechnology] is valued at $587.85M. EDIT’s [@Biotechnology] market capitalization is $108.14M. The market cap for tickers in the [@Biotechnology] industry ranges from $464.4B to $0. The average market capitalization across the [@Biotechnology] industry is $2.57B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALT’s FA Score shows that 0 FA rating(s) are green whileEDIT’s FA Score has 1 green FA rating(s).

  • ALT’s FA Score: 0 green, 5 red.
  • EDIT’s FA Score: 1 green, 4 red.
According to our system of comparison, both ALT and EDIT are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALT’s TA Score shows that 5 TA indicator(s) are bullish while EDIT’s TA Score has 4 bullish TA indicator(s).

  • ALT’s TA Score: 5 bullish, 4 bearish.
  • EDIT’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, both ALT and EDIT are a good buy in the short-term.

Price Growth

ALT (@Biotechnology) experienced а -8.47% price change this week, while EDIT (@Biotechnology) price change was -9.03% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.20%. For the same industry, the average monthly price growth was -1.27%, and the average quarterly price growth was +2.17%.

Reported Earning Dates

ALT is expected to report earnings on Mar 27, 2025.

EDIT is expected to report earnings on Feb 26, 2025.

Industries' Descriptions

@Biotechnology (-2.20% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ALT($588M) has a higher market cap than EDIT($108M). ALT YTD gains are higher at: -26.533 vs. EDIT (-87.068). ALT has higher annual earnings (EBITDA): -103.19M vs. EDIT (-222.63M). EDIT has more cash in the bank: 265M vs. ALT (139M). ALT has less debt than EDIT: ALT (1.77M) vs EDIT (38.5M). EDIT has higher revenues than ALT: EDIT (61.8M) vs ALT (52K).
ALTEDITALT / EDIT
Capitalization588M108M544%
EBITDA-103.19M-222.63M46%
Gain YTD-26.533-87.06830%
P/E RatioN/AN/A-
Revenue52K61.8M0%
Total Cash139M265M52%
Total Debt1.77M38.5M5%
FUNDAMENTALS RATINGS
ALT vs EDIT: Fundamental Ratings
ALT
EDIT
OUTLOOK RATING
1..100
6951
VALUATION
overvalued / fair valued / undervalued
1..100
97
Overvalued
14
Undervalued
PROFIT vs RISK RATING
1..100
74100
SMR RATING
1..100
9898
PRICE GROWTH RATING
1..100
4497
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EDIT's Valuation (14) in the Biotechnology industry is significantly better than the same rating for ALT (97) in the Miscellaneous Commercial Services industry. This means that EDIT’s stock grew significantly faster than ALT’s over the last 12 months.

ALT's Profit vs Risk Rating (74) in the Miscellaneous Commercial Services industry is in the same range as EDIT (100) in the Biotechnology industry. This means that ALT’s stock grew similarly to EDIT’s over the last 12 months.

ALT's SMR Rating (98) in the Miscellaneous Commercial Services industry is in the same range as EDIT (98) in the Biotechnology industry. This means that ALT’s stock grew similarly to EDIT’s over the last 12 months.

ALT's Price Growth Rating (44) in the Miscellaneous Commercial Services industry is somewhat better than the same rating for EDIT (97) in the Biotechnology industry. This means that ALT’s stock grew somewhat faster than EDIT’s over the last 12 months.

ALT's P/E Growth Rating (100) in the Miscellaneous Commercial Services industry is in the same range as EDIT (100) in the Biotechnology industry. This means that ALT’s stock grew similarly to EDIT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALTEDIT
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
80%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
75%
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
N/A
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
90%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
88%
Bearish Trend 1 day ago
89%
Advances
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 5 days ago
77%
Declines
ODDS (%)
Bearish Trend 4 days ago
88%
Bearish Trend 1 day ago
89%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
83%
Aroon
ODDS (%)
Bullish Trend 1 day ago
79%
Bearish Trend 1 day ago
90%
View a ticker or compare two or three
Ad is loading...
ALT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EDIT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
AMOMX21.830.27
+1.25%
AQR Large Cap Momentum Style I
KTCIX47.510.53
+1.13%
DWS Science and Technology Inst
LFFLX13.400.14
+1.06%
Lord Abbett Focused Large Cap Value F
WFEFX12.36-0.04
-0.32%
Allspring International Equity C
BBVSX14.42-0.80
-5.26%
Bridge Builder Small/Mid Cap Value

EDIT and

Correlation & Price change

A.I.dvisor indicates that over the last year, EDIT has been loosely correlated with NTLA. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if EDIT jumps, then NTLA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EDIT
1D Price
Change %
EDIT100%
-2.24%
NTLA - EDIT
63%
Loosely correlated
+1.08%
CRSP - EDIT
59%
Loosely correlated
+0.83%
BEAM - EDIT
56%
Loosely correlated
+8.16%
AURA - EDIT
53%
Loosely correlated
+1.23%
AXON - EDIT
52%
Loosely correlated
+2.59%
More